Clinical Cardiology Alert – February 1, 2013
February 1, 2013
View Issues
-
CABG beats PCI in Diabetics with Multivessel CAD
Among patients with coronary artery disease (CAD), those with diabetes are at higher risk for adverse outcomes. Thus, it is important to find the optimal treatment strategy for this high-risk group to improve their prognosis. -
Apixaban vs Warfarin for Atrial Fibrillation
Atrial fibrillation (AF) and stroke are common in patients with chronic kidney disease (CKD), but many such patients are not anticoagulated for fear of bleeding complications. -
Clopidogrel for Saphenous Vein Graft PCI
Saphenous vein graft patency after coronary artery bypass grafting failure rates are as high as 40% at 18 months. How many of these failures are due to the discontinuation of clopidogrel is the subject of this observational study done at a regional heart center in the Southern California Kaiser system that includes detailed pharmacy records. -
Contemporary Prevalence of Atherosclerosis in Military Personnel at Autopsy
Autopsy studies from the Korea and Vietnam wars, which demonstrated that atherosclerosis begins in teens and young adults, have revolutionized our understanding of the pathogenesis and progression of coronary artery disease (CAD). -
Risk of Ventricular Tachyarrhythmias after Cardiac Surgery
This paper reviews the experience at a large cardiac surgery center with ventricular arrhythmias in the postoperative period. The authors searched the Society of Thoracic Surgeons (STS) adult cardiac database for all patients undergoing cardiac surgery at Emory University between January 2004 and July 2010. -
Fidelis Lead Fracture Risk
The Medtronic Sprint Fidelis Lead (Model 6949) is known to have a high rate of lead fracture. In this paper, the authors look at survival of the Sprint Fidelis lead in the setting of a third lead for cardiac resynchronization. -
Pharmacology Watch: FDA Approves Apixaban for Patients with Nonvalvular AF
Apixaban approval; new dental clinical practice guideline; apixaban for VTE; aspirin resistance; tamoxifen treatment; and FDA actions. -
Clinical Briefs in Primary Care Supplement